ERBB2 and breast carcinoma: A phase Ib trial, when lumretuzumab was added with pertuzumab and paclitaxel in 35 patients with HER3-positive HER2-low breast cancer, demonstrated a high incidence of diarrhea and a narrow therapeutic window [141].